Patients with cancer who receive chemotherapy frequently develop anaemia (Gale, 1985) . It can significantly contribute to their morbidity and they often require haemotransfusions. Cisplatin (CDDP) treatment is one of the most common cause of chemotherapy-induced anaemia. In about 40% of patients in fact anaemia develops during the treatment and most of them require packed RBC transfusions (Rossof et al., 1972; Von Hoff et al., 1979) . The anaemia associated with CDDP therapy is a normochromic, normocytic, hypoproliferative anaemia with a low reticulocyte count, similar to that seen in patients with chronic renal failure (Rossof et al., 1972; Eschbach et al., 1989) . Although the etiology of this anaemia is probably multifactorial, some studies showed that in this anaemia the increase linear relationship between the concentrations of haemoglobin and those of circulating erythropoietin, that is observed in the other anaemic states (iron deficiency; acute blood loss and hemolysis), was not present in the same way of the anaemia of chronic renal failure (Alexopoulos et al., 1986; Miller et al., 1990; Platanias et al., 1991) .
In the animal models of CDDP-associated anaemia, the treatment with exogenous recombinant erythropoietin has resulted in reversal of the anaemia (Matsumoto et al., 1990) . Recently a phase I-II study about treatment of CDDPinduced anaemia with erythropoietin administered intravenously confirmed that erythropoietin is effective and well tolerated in this condition (Miller et al., 1992) .
We report the results of a pilot study of subcutaneous erythropoietin in the treatment of CDDP-induced anaemia. Efficacy Table II shows haemoglobin levels on day 1 and after three weeks of rHuEPO therapy.
Patients and methods

Patients
Fifteen patients obtained an increase in haemoglobin to above 100gl-', which was considered as a clinical response in this study, with a dose of 50 U Kg-' and one required a dose of 100 U Kg-'. Only three patients required haemotransfusions and were considered non responders (Table   II) .
These haemoglobin increases occurred despite continuation of CDDP chemotherapy.
Discussion
About 40% of patients develop anaemia during the chemotherapy with cisplatin containing regimens. It can be a dominant factor in symptoms and morbidity and most of patients can require red blood cell transfusions (Von Hoff et al., 1979; Rossof et al., 1972) .
Although the mechanism of CDDP-induced anaemia is not well known, it appears that inadequate erythropoietin response is important in the developing of this anaemia. In the same way of chronic renal failure associated anaemia (Eschbach et al., 1989) in CDDP-induced anaemia the linear relation between the concentrations of haemoglobin and those of circulating erythropoietin is not present and, despite anaemia, low levels of erythropoietin in plasma have been shown (Miller et al., 1990; Platanias et al., 1991; Matsumoto et al., 1990; Miller et al., 1992; Rothmann et al., 1985) . This inadequate response was thought to be due to cisplatinassociated nephrotoxicity (Platanias et al., 1991) . However in the study of Miller (1992) and in our study, renal function appeared to be normal during cisplatin treatment, although subclinical nephrotoxicity could not be excluded. Moreover the erythropoietin response to anaemia was similar in the patients receiving chemotherapy whether or not the treatment included cisplatin (Platanias et al., 1991) . This suggests that chemotherapy may have an effect on the erythropoietin response to anaemia that is independent of therapy-induced nephrotoxicity.
Treatment with exogenous rHuEPO has resulted in reversal of the anaemia in the animal models of CDDP-associated anaemia (Matsumoto et al., 1990) .
Recently Miller (1992) showed the efficacy of intravenous erythropoietin in the treatment of CDDP-induced anaemia. Twelve out of 21 patients obtained an increase of haemoglobin levels with a mild toxicity.
In our study we chose a subcutaneous route of rHuEPO administration because it was shown to be effective and safe in the treatment of anaemia associated with chronic renal failure, myeloma and other haematological diseases, and for convenience because it can be administered on an outpatient basis (Eschbach et al., 1989; Ludwig et al., 1990; Cazzola et al., 1992) . Furthermore rHuEPO subcutaneous injections result in slow release from subcutaneous depots, providing lower but more sustained plasma levels than intravenous injections. In fact the pharmacokinetics of intravenously administered rHuEPO are characterised by brief peaks in plasma levels due to the relatively small distribution volume, about the same as the plasma volume, and the short half-life of about 6 to 8 h (McMahon et al., 1990; Erslev, 1991) . For these reasons subcutaneous administration can be advantageous because even lower doses may be sufficient for a certain erythropoietic effect.
The low dose was chosen on the basis of data reported above and of preclinical findings that showed low doses rHuEPO were sufficient for recovering from CDDP-induced anaemia, whereas higher doses were required for the treatment of 5-fluorouracil induced anaemia or other cytotoxic drugs (Matsumoto et al., 1990) .
In our study we obtained the remission of anaemia in 17 out of 20 patients with mild side effects. In 15 patients a dose of 50 U Kg-' three times a week was sufficient to maintain haemoglobin levels higher than 100 g-'. In one patient a dose of 75 UKg-I and in one patient a dose of 100 UKg-I needed, while three patients were considered non responders and required haemotransfusions.
Moreover it is of interest that our results seem to confirm data obtained by Miller (1992) on the lack of prediction of pretreatment erythropoietin levels to exogenous rHuEPO in patients with CDDP anaemia. In fact in our study two out of the three non responder patients presented the lowest levels of pretreatment serum erythropoietin. These data are consistent also with the reports by Ludwig (1990) and Oster (1990) . The findings of the present study show the effectiveness and the safety of subcutaneous administration of rHuEPO even with a lower dose respect to that demonstrated effective by intravenous route. In fact while in Miller's study (1992) doses of 100 U Kg-' and 200 U Kg-' five times weekly offered the potentiation for optimal clinical response, in our study doses of 50-75 U Kg'-three times a week were sufficient to obtain a clinical response. For this reasons subcutaneous rHuEPO could be more convenient than intravenous administration, also considering the economic aspect. Considering that in our study 75 U Kg-' three times a week could be the optimal dose whereas in Miller's study the erythropoietin dose should be at least 100 U Kg-' five times a week, one week treatment requires the use of 225 U Kg-Iin our regimen and 500 U Kg-' in Miller's regimen for each patient. Because in Italy the price of 1,000 U of rHuEPO is about $14 for hospital pharmacies intravenous regimen is surely more expensive.
On the basis of these data further trials seem to be recommended to define the optimal dose and route of administration in view of determining, by randomised studies, the real effect on transfusion requirements and chemotherapy administration.
